<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04205565</url>
  </required_header>
  <id_info>
    <org_study_id>PHMS201614F</org_study_id>
    <nct_id>NCT04205565</nct_id>
  </id_info>
  <brief_title>Study on Clinical Effectiveness of L-Oxiracetam Injection</brief_title>
  <official_title>A Randomized, Double-blind, Positive Drug/Placebo Parallel Controlled, Multicenter, Phase II Exploratory Clinical Trial of L-oxiracetam Injection to Improve Memory and Cognitive Impairment in Patients With Craniocerebral Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Yoko Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Yoko Biomedical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, positive drug/placebo parallel controlled, multicenter, phase II
      exploratory clinical trial of L-oxiracetam injection to improve memory and cognitive
      Impairment in patients with craniocerebral injury.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 26, 2017</start_date>
  <completion_date type="Anticipated">March 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference of Loewenstein Occupational Therapy Cognitive Assessment (LOCTA) scores between baseline and 3 months after administration of drugs.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Craniocerebral Injury</condition>
  <arm_group>
    <arm_group_label>L-oxiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Plaecbo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose group: L-oxiracetam Injection</intervention_name>
    <description>L-oxiracetam injection, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.</description>
    <arm_group_label>L-oxiracetam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose group: L-oxiracetam Injection</intervention_name>
    <description>L-oxiracetam injection, 3 vials, once a day, IV. Placebo injection of l-oxiracetam, 1 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.</description>
    <arm_group_label>L-oxiracetam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control group: Oxiracetam Injection</intervention_name>
    <description>Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Oxiracetam injection, 6 vials, once a day, IV.</description>
    <arm_group_label>Oxiracetam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo group: Placebo Injection</intervention_name>
    <description>Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.</description>
    <arm_group_label>Plaecbo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75 years old (including upper and lower limits), male or female

          2. Craniocerebral injury meets all of the following conditions: This diagnosis has a
             clear head trauma, closed head injury, or head injury with cerebrospinal fluid ear
             leak and / or nasal leak and / or intracranial gas accumulation; MRI or CT confirmed
             intracranial hemorrhage above the cerebellum (including cerebral contusion,
             subarachnoid hemorrhage, epidural hematoma, subdural hemorrhage, intracranial
             hematoma, etc.), with or without transient coma; Craniocerebral injury is classified
             as mild or moderate (GCS score 10-15 points); Conservative treatment.

          3. Within 72 hours after head injury, patients with stable and mentally handicapped
             mental state examination (MMSE) scores are lower than normal.

          4. The legal representative and / or patient agree to participate in this clinical trial
             and sign an informed consent form.

        Exclusion Criteria:

          1. People who are known or suspected to be allergic to the test drug and its ingredients.

          2. After the injury, drugs that improve cognitive function such as the prohibited drugs
             listed in the protocol have been used.

          3. With a history of severe traumatic brain injury, a history of cerebrovascular
             accidents, and structural craniocerebral lesions.

          4. With diseases such as speech and hearing impairment that cannot cooperate with the
             completion of cognitive function assessment.

          5. A secondary brain injury occurred after the craniocerebral injury.

          6. Those who need craniotomy or extraventricular drainage.

          7. Combining with other serious large organ damage or serious complications may affect
             the test Life.

          8. Patients with active epilepsy who had seizures within 1 year.

          9. Patients with severe liver and kidney disease.

         10. Complicated with severe heart disease, lung disease, blood and hematopoietic diseases,
             gastrointestinal disease, serious or progressive disease.

         11. Past or present with a malignant tumor

         12. Combining neurological and mental disorders that make it impossible or unwilling to
             cooperate.

         13. Women who are pregnant, breastfeeding or have a recent birth plan.

         14. Researchers do not consider it appropriate to participate in the clinical trial.

         15. Those who have participated in other clinical trials and used test drugs 3 months
             before the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>General Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjing</city>
        <state>Tianjing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>L-oxiracetam</keyword>
  <keyword>Cognitive Impairment</keyword>
  <keyword>Craniocerebral Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Craniocerebral Trauma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxiracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

